<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868906</url>
  </required_header>
  <id_info>
    <org_study_id>TC-FMISO-PET-06-1413</org_study_id>
    <secondary_id>2009-015852-11</secondary_id>
    <secondary_id>PI 06/1413, PI 12/02940</secondary_id>
    <secondary_id>TC-FMISO-PET-06-1413</secondary_id>
    <nct_id>NCT01868906</nct_id>
  </id_info>
  <brief_title>FMISO-PET in Brain Tumors and SCS Effect</brief_title>
  <acronym>FMISOPETSCS</acronym>
  <official_title>Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernardino Clavo, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo de Investigación Clínica en Oncología Radioterapia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Canario de Investigación del Cáncer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RSbiomed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación DISA, Canary Islands, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Negrin University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess, with 18F-FMISO PET, hypoxia in high grade gliomas and
      changes by spinal cord stimulation in a subset of patients. Additionally, the potential
      correlation with pathological, imaging and clinical parameters will be analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumour ischaemia-hypoxia decreases the efficacy of radio-chemotherapy. Polarographic probe
      (and some 18F-FMISO-PET) studies have demonstrated prognostic value. Additionally hypoxia
      modification may increase survival. However, in high grade gliomas (HGG) there are not well
      established methods to evaluate and modify tumor hypoxia. We have previously described how
      spinal cord stimulation (SCS) can modify oxygenation, blood flow and metabolism in malignant
      gliomas. The aim of this study is to assess with 18F-FMISO PET: hypoxia in HGG and changes by
      spinal cord stimulation in a subset of patients. Additionally, the potential correlation with
      pathological, imaging and clinical parameters will be analyzed.

      18F-FMISO PET will be performed in 20 patients with diagnosis of HGG: after surgery/biopsy
      and before radical treatment with 3D radiotherapy and temozolomide. A subset of 10 patients
      undergo two studies with 18F- FMISO-PET (one with SCS &quot;off&quot; and one with SCS &quot;on&quot;). In these
      patients, SCS will be connected from 1 hour before to 1 hour after each radiotherapy session,
      and in the day-time during the days of adjuvant temozolomide.

      18F-FMISO PET results will not be taking into account for patient management. Patients will
      be followed at least until the end of adjuvant temozolomide (6 months after the end of
      concurrent radiochemotherapy).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Isotope (FMISO) production is no longer available in our country.
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor hypoxia measurement using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio). Baseline measurement.</measure>
    <time_frame>18F-FMISO-PET between 1 and 3 weeks before the commencement of radio-chemotherapy</time_frame>
    <description>Tumor hypoxia will be measured in 20 patients with HGG using 18F-FMISO-PET: after biopsy or surgery and before the commencement of radio-chemotherapy. It will be assessed the prevalence and extent of significant hypoxia in HGG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline tumor hypoxia using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio) during SCS.</measure>
    <time_frame>2nd 18F-FMISO-PET between 1 and 7 days after the 1st 18F-FMISO-PET</time_frame>
    <description>A subset of 10 patients will undergo a second 18F-FMISO-PET study during spinal cord stimulation to evaluate changes by SCS between 1 and 7 days after the first 18F-FMISO-PET study (and before the commencement of radio-chemotherapy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between 18F-FMISO-PET values and pathological tumor parameters</measure>
    <time_frame>Week 0 (at the commencement of radio-chemotherapy).</time_frame>
    <description>To analyze the correlation of 18F-FMISO-PET with histological parameters and tumor expression of: CD31 (vascular density), VEGF (vascular endothelial growth factor) and VEGFR (angiogenesis), EGFR (epidermal growth factor receptor), Ki-67 (proliferation index) and hypoxic markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with Karnofsky scale.</measure>
    <time_frame>At 0, 2 and 9 months after the commencement of the radio-chemotherapy.</time_frame>
    <description>To analyze the correlation with performance status using the Karnofsky scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with the ECOG (Eastern Cooperative Oncology Group) performance status scale</measure>
    <time_frame>At 0, 2 and 9 months after the commencement of the radio-chemotherapy</time_frame>
    <description>To analyze the correlation with performance status using the ECOG (WHO) scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with the Quality of Life Questionnaire QLQ-C30 (EORTC)</measure>
    <time_frame>At 0, 2 and 9 months after the commencement of the radio-chemotherapy.</time_frame>
    <description>To analyze the correlation with quality of life using the QLQ-C30 (EORTC) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>At 9 months after the commencement of the radio-chemotherapy.</time_frame>
    <description>To analyze the correlation with overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response to treatment</measure>
    <time_frame>9 months after the commencement of radio-chemotherapy</time_frame>
    <description>To analyze the correlation between 18F-FMISO-PET values and radiological response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological location of tumor relapse or progression</measure>
    <time_frame>9 months after the commencement of radio-chemotherapy</time_frame>
    <description>To analyze the correlation between 18F-FMISO-PET values and the radiological location of tumor relapse or progression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood flow in carotid and middle cerebral arteries</measure>
    <time_frame>Between 1 and 3 weeks before the commencement of radio-chemotherapy</time_frame>
    <description>To analyze the correlation between 18F-FMISO-PET values and blood flow in carotid and middle cerebral arteries (assessed before the commencement of radio-chemotherapy) using Doppler measurements.</description>
  </other_outcome>
  <other_outcome>
    <measure>Facial and supraciliar infrared emission</measure>
    <time_frame>Between 1 and 3 weeks before the commencement of radio-chemotherapy</time_frame>
    <description>To analyze the correlation between 18F-FMISO-PET values and facial and supraciliar infrared emission (assessed by digital thermography)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>Arm-A: 18F-FMISO-PET without SCS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-B: 18F-FMISO-PET without/with SCS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one &quot;without&quot; and one &quot;with&quot; spinal cord stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FMISO</intervention_name>
    <description>18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.</description>
    <arm_group_label>Arm-A: 18F-FMISO-PET without SCS</arm_group_label>
    <arm_group_label>Arm-B: 18F-FMISO-PET without/with SCS</arm_group_label>
    <other_name>Fluoromisonidazole</other_name>
    <other_name>FMISO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET without SCS</intervention_name>
    <description>PET-scanning using 18F-fluoromisonidazole without SCS</description>
    <arm_group_label>Arm-A: 18F-FMISO-PET without SCS</arm_group_label>
    <arm_group_label>Arm-B: 18F-FMISO-PET without/with SCS</arm_group_label>
    <other_name>Positron emission tomography scanning</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SCS</intervention_name>
    <description>Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.</description>
    <arm_group_label>Arm-B: 18F-FMISO-PET without/with SCS</arm_group_label>
    <other_name>Electrical Neurostimulation</other_name>
    <other_name>Spinal Cord Stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET without/with SCS</intervention_name>
    <description>Second PET-scanning using 18F-fluoromisonidazole: without/with SCS</description>
    <arm_group_label>Arm-B: 18F-FMISO-PET without/with SCS</arm_group_label>
    <other_name>Positron emission tomography scanning</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Standard radiation therapy</description>
    <arm_group_label>Arm-A: 18F-FMISO-PET without SCS</arm_group_label>
    <arm_group_label>Arm-B: 18F-FMISO-PET without/with SCS</arm_group_label>
    <other_name>Radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Standard treatment with concurrent and adjuvant Temozolomide.</description>
    <arm_group_label>Arm-A: 18F-FMISO-PET without SCS</arm_group_label>
    <arm_group_label>Arm-B: 18F-FMISO-PET without/with SCS</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temcad</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologically confirmed (first presentation or relapsed) high grade
             glioma (Grade III or Grade IV according WHO criteria) proposed for radical treatment
             with 3D radiotherapy and temozolomide.

          -  Patients 18-75 years old.

          -  Karnofsky &gt;= 60% and ECOG =&lt; 2.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Clinical or psychological contraindications to fly (if 18F-FMISO-PET is realized in
             Madrid) or to SCS-placement (only for this subset).

          -  Pregnant or breastfeeding women and women of fertile age who are not using a safe
             contraceptive method or do not intend to use one during the trial. Safe contraceptive
             methods are oral or parenteral contraceptive treatments or barrier methods: masculine
             or feminine condom, diaphragm and/or intrauterine device (IUD) or withdrawal over the
             course of the study.

          -  Serious co-existing or concurrent illness, including any of the following:
             uncontrolled or severe infection, heart, liver or kidney disease

          -  Lung thromboembolism.

          -  Another malignancy in the last 5 years other than basal cell or squamous cell
             carcinoma of the skin or carcinoma in situ of the cervix.

          -  Patients with life expectancy &lt;3 months.

          -  Patients with any of the following: creatinine &gt; 2 mg/dl, neutrophils &lt;1.5 * 10^9/L,
             platelets &lt;100 * 10^9/L or hemoglobin &lt;8.5 g/dL.

          -  Contraindications to receive radiotherapy or chemotherapy Clinical or psychological
             contraindications for placement of spinal cord stimulation devices (only for that
             specific subset of patients).

          -  Patients who are unable or unwilling to meet the protocol study.

          -  Patients who do not meet all the inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernardino Clavo, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dr. Negrin University Hospital, Las Palmas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernardino Clavo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Negrin University Hospital, Las Palmas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Robaina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Negrin University Hospital, Las Palmas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan C Alonso, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Negrin University Hospital</name>
      <address>
        <city>Las Palmas</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28.033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Clavo B, Robaina F, Morera J, Ruiz-Egea E, Pérez JL, Macías D, Caramés MA, Catalá L, Hernández MA, Günderoth M. Increase of brain tumor oxygenation during cervical spinal cord stimulation. Report of three cases. J Neurosurg. 2002 Jan;96(1 Suppl):94-100.</citation>
    <PMID>11795721</PMID>
  </reference>
  <reference>
    <citation>Clavo B, Robaina F, Catalá L, Valcárcel B, Morera J, Caramés MA, Ruiz-Egea E, Panero F, Lloret M, Hernández MA. Increased locoregional blood flow in brain tumors after cervical spinal cord stimulation. J Neurosurg. 2003 Jun;98(6):1263-70.</citation>
    <PMID>12816274</PMID>
  </reference>
  <reference>
    <citation>Clavo B, Robaina F, Catalá L, Pérez JL, Lloret M, Caramés MA, Morera J, López L, Suárez G, Macías D, Rivero J, Hernández MA. Effect of cervical spinal cord stimulation on regional blood flow and oxygenation in advanced head and neck tumours. Ann Oncol. 2004 May;15(5):802-7.</citation>
    <PMID>15111351</PMID>
  </reference>
  <reference>
    <citation>Clavo B, Robaina F, Montz R, Domper M, Carames MA, Morera J, Pinar B, Hernandez MA, Santullano V, Carreras JL. Modification of glucose metabolism in brain tumors by using cervical spinal cord stimulation. J Neurosurg. 2006 Apr;104(4):537-41.</citation>
    <PMID>16619657</PMID>
  </reference>
  <reference>
    <citation>Robaina F, Clavo B, Catalá L, Caramés MÁ, Morera J. Blood flow increase by cervical spinal cord stimulation in middle cerebral and common carotid arteries. Neuromodulation. 2004 Jan;7(1):26-31. doi: 10.1111/j.1525-1403.2004.04003.x.</citation>
    <PMID>22151123</PMID>
  </reference>
  <reference>
    <citation>Clavo B, Robaina F, Montz R, Carames MA, Otermin E, Carreras JL. Effect of cervical spinal cord stimulation on cerebral glucose metabolism. Neurol Res. 2008 Jul;30(6):652-4. doi: 10.1179/174313208X305373. Epub 2008 May 29.</citation>
    <PMID>18513465</PMID>
  </reference>
  <reference>
    <citation>Clavo B, Robaina F, Montz R, Carames MA, Lloret M, Ponce P, Hernandez MA, Carreras JL. Modification of glucose metabolism in radiation-induced brain injury areas using cervical spinal cord stimulation. Acta Neurochir (Wien). 2009 Nov;151(11):1419-25. doi: 10.1007/s00701-009-0400-8. Epub 2009 Jun 5.</citation>
    <PMID>19499176</PMID>
  </reference>
  <reference>
    <citation>Clavo B, Robaina F, Valcarcel B, Catala L, Perez JL, Cabezon A, Jorge IJ, Fiuza D, Hernandez MA, Jover R, Carreras JL. Modification of loco-regional microenvironment in brain tumors by spinal cord stimulation. Implications for radio-chemotherapy. J Neurooncol. 2012 Jan;106(1):177-84. doi: 10.1007/s11060-011-0660-z. Epub 2011 Jul 12.</citation>
    <PMID>21748490</PMID>
  </reference>
  <reference>
    <citation>Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007 Sep 10;25(26):4066-74. Review.</citation>
    <PMID>17827455</PMID>
  </reference>
  <reference>
    <citation>Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL, Krohn KA. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008 May 1;14(9):2623-30. doi: 10.1158/1078-0432.CCR-07-4995.</citation>
    <PMID>18451225</PMID>
  </reference>
  <reference>
    <citation>Clavo B, Robaina F, Jorge IJ, Cabrera R, Ruiz-Egea E, Szolna A, Otermin E, Llontop P, Carames MA, Santana-Rodríguez N, Sminia P. Spinal cord stimulation as adjuvant during chemotherapy and reirradiation treatment of recurrent high-grade gliomas. Integr Cancer Ther. 2014 Nov;13(6):513-9. doi: 10.1177/1534735414550037. Epub 2014 Sep 15.</citation>
    <PMID>25228535</PMID>
  </reference>
  <reference>
    <citation>Clavo B, Robaina F, Fiuza D, Ruiz A, Lloret M, Rey-Baltar D, Llontop P, Riveros A, Rivero J, Castañeda F, Quintero S, Santana-Rodríguez N. Predictive value of hypoxia in advanced head and neck cancer after treatment with hyperfractionated radio-chemotherapy and hypoxia modification. Clin Transl Oncol. 2017 Apr;19(4):419-424. doi: 10.1007/s12094-016-1541-x. Epub 2016 Aug 15.</citation>
    <PMID>27527617</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Negrin University Hospital</investigator_affiliation>
    <investigator_full_name>Bernardino Clavo, MD, PhD</investigator_full_name>
    <investigator_title>Radiation Oncologist, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Anaplastic Astrocytoma</keyword>
  <keyword>Brain Tumors</keyword>
  <keyword>Cancer Imaging</keyword>
  <keyword>Fluoromisonidazole</keyword>
  <keyword>FMISO PET</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>High Grade Glioma</keyword>
  <keyword>Hypoxia Modification</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Radiation-Sensitizing Agents</keyword>
  <keyword>Spinal Cord Stimulation</keyword>
  <keyword>Tumor Hypoxia Measurement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Misonidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

